DOP31: Development and validation of the IBD-REFER criteria: when should a general practitioner or paediatrician refer a patient for suspected IBD?
ECCO '19 Copenhagen
2019
DOP32: Withdrawal of thiopurines in Crohn’s disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2)
ECCO '19 Copenhagen
2019
DOP33: Long-term clinical efficacy of ustekinumab in refractory Crohn’s disease : a multi-centre Belgian cohort study
ECCO '19 Copenhagen
2019
DOP34: Disease activity patterns during the first 5 years after diagnosis in children with ulcerative colitis: a population-based study
ECCO '19 Copenhagen
2019
DOP35: Innate immune dysregulation, detectable up to 6 years before the diagnosis of Crohn’s disease, is significantly amplified in patients with a complicated phenotype
ECCO '19 Copenhagen
2019
DOP36: Gut microbial variations in patients with quiescent Crohn’s disease predict subsequent disease flare
ECCO '19 Copenhagen
2019
DOP37: Vedolizumab-induced endoscopic remission in anti-TNF exposed and anti-TNF naïve IBD patients: a large single-centre experience
ECCO '19 Copenhagen
2019
DOP38: A vedolizumab specific four-gene colonic signature accurately predicting future endoscopic remission in patients with inflammatory bowel disease
ECCO '19 Copenhagen
2019
DOP39: Safety of combination biologic and anti-rejection therapy post-liver transplantation in patients with inflammatory bowel disease: London Ontario experience
ECCO '19 Copenhagen
2019
DOP40: Effectiveness and safety of reference infliximab and biosimilar in Crohn’s disease: a French equivalence study
ECCO '19 Copenhagen
2019
DOP42: Dietary therapies induce rapid response and remission in active paediatric Crohn’s disease
ECCO '19 Copenhagen
2019
DOP43: Long-term efficacy of tofacitinib in patients who received extended induction therapy: results of the OCTAVE open study for tofacitinib delayed responders
ECCO '19 Copenhagen
2019
DOP44: Efficacy and safety of tacrolimus in ulcerative colitis: a nationwide, multi-centre study from GETECCU
ECCO '19 Copenhagen
2019
DOP45: Adequate infliximab exposure during the induction phase is associated with early complete fistula response in patients with fistulizing Crohn’s disease: a post-hoc analysis of the ACCENT-2 trial
ECCO '19 Copenhagen
2019
DOP46: Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trial
ECCO '19 Copenhagen
2019
DOP47: Sustained remission in patients with moderate to severe ulcerative colitis: Results from the Phase 3 UNIFI maintenance study
ECCO '19 Copenhagen
2019
DOP48: Amiselimod, a selective S1P receptor modulator in Crohn’s disease patients: a proof-of-concept study
ECCO '19 Copenhagen
2019